AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer

Impact · against what's priced in

The FDA breakthrough designations for Temab-A provide a positive catalyst for AbbVie by validating a late-stage oncology asset that the market has previously discounted. While positive Phase III data for etentamig is likely already reflected in revenue expectations, the specific acceleration of Temab-A in CRC and NSCLC provides incremental upside.

ABBV+0.40

Challenges what's priced in

The price assumes

Late-stage oncology catalysts, including ABBV-706 in small cell lung cancer and RC148 in squamous NSCLC

The market isn't currently paying for late-stage oncology catalysts, so the granting of two Breakthrough Therapy designations for Temab-A in colorectal and non-small cell lung cancer provides a tangible catalyst for a previously discounted segment of the pipeline.

What ABBV's price assumes · Sep 4

• healthcare
• biotech
• ABBV
• antibody drug conjugates
• breakthrough therapy
• cancer research
• colorectal cancer
• fda
• lung cancer
• oncology

Search tags